Amlodipine treatment of hypertension associates with a decreased dementia risk

References

• Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;27(347):1141–1145.
   Web of Science ®Google Scholar
• Hanon O, Seux ML, Lenoir H, et al. Hypertension and dementia. Curr Cardiol Rep 2003;5:435–440.
   PubMedGoogle Scholar
• Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487–499.
   PubMed Web of Science ®Google Scholar
• Peters R, Beckett N, Forette F, et al.; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683–689.
   PubMed Web of Science ®Google Scholar
• McGuiness B, Todd S, Passmore P, Bullok R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Datab Syst Rev 2009;CD004034.
   Google Scholar
• Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009;9:1413–1431.
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–1351.
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, et al.; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046–2052.
   Google Scholar
• Schrader J, Lüders S, Kulschewski A, et al.; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–1226.
   PubMed Web of Science ®Google Scholar
• Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005;26:157–163.
   PubMed Web of Science ®Google Scholar
• Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 2011;17(3–4):149–162.
   PubMed Web of Science ®Google Scholar
• ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31:1925–1938.
   Google Scholar
• Kohler S, Baars M, Spauwen P, et al. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. Hypertension, 2014;63:245–251.
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, et al.; Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503):2112–2117.
   PubMed Web of Science ®Google Scholar
• Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379–397.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68:991–998.
   PubMed Web of Science ®Google Scholar
• Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens 2014;32:1945–1957.
   PubMed Web of Science ®Google Scholar
• Khactaturian A, Zandi P, Lyketsos C, et al. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol, 2006;63:686–692.
   PubMedGoogle Scholar
• Yasar S, Xia J, Yao W, et al.; Ginkgo Evaluation of Memory (GEM) Study Investigators. Antihypertensive drugs decrease risk of Alzheimer’s disease: Ginkgo evaluation on memory study. Neurol, 2013;81:896–903.
   Google Scholar
• Gelber R, Ross G, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment. The Honolulu-Asia Aging Study. Neurol 2013;81:1–8.
   Google Scholar
• Haag M, Hofman A, Koudstaal P, et al. Duration of antihypertensive drug use and risk of dementia. Neurol 2009;72:1727–1734.
   PubMed Web of Science ®Google Scholar
• Maxwell C, Hogan D, Ebly E. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ 1999;161:501–506.
   PubMed Web of Science ®Google Scholar
• Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol 2013;169:1203–1210.
   PubMed Web of Science ®Google Scholar
• Toescu EC, Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 2007;6:267–273.
   PubMed Web of Science ®Google Scholar
• Small DH, Gasperini R, Vincent AJ, et al. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 2009;16:225–233.
   PubMed Web of Science ®Google Scholar
• Harkany T, Abrahám I, Kónya C, et al. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 2000;11:329–382.
   PubMed Web of Science ®Google Scholar
• Asakura K, Matsuo Y, Kanemasa T, Ninomiya M. P/Q-type Ca2+ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats. Brain Res, 1997;776:140–145.
   PubMed Web of Science ®Google Scholar
• Berman RF, Verweij BH, Muizelaar JP. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg 2000;93:821–828.
   PubMed Web of Science ®Google Scholar
• Verweij BH, Muizelaar JP, Vinas FC, et al. Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury. J Neurosurg 2000;93:829–834.
   PubMed Web of Science ®Google Scholar
• McKhann G, Knopman D, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–269.
   PubMed Web of Science ®Google Scholar
• Levi-Marpillat N, Macquin-Mavier I, Tropeano A, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens, 2013;31:1073–1082.
   PubMed Web of Science ®Google Scholar
• Hanyu H, Hirao K, Shimizu S, et al. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psyhiatry, 2007;22:1264–1266.
   PubMed Web of Science ®Google Scholar